2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-12171741-B2 · Dec 24, 2024 · US
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
US10058534B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10058534-B2 |
| Application number | US-201815898561-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 17, 2018 |
| Priority date | Feb 19, 2013 |
| Publication date | Aug 28, 2018 |
| Grant date | Aug 28, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds of formula I: in which n, m, X, Y 1 , R 1 , R 2 , R 3 , R 4 and R 5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
First claim
Opening claim text (preview).
We claim: 1. A method of treating breast cancer comprising administering to a subject in need of such treatment an effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the structure: in combination with 2-Methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile.
Assignees
Inventors
Classifications
not condensed and containing further heterocyclic rings, e.g. cromakalim · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
linked by a carbon chain containing aromatic rings · CPC title
Oxadiazoles · CPC title
containing a heterocyclic ring having sulfur as a ring hetero atom · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10058534B2 cover?
- The present invention relates to compounds of formula I: in which n, m, X, Y 1 , R 1 , R 2 , R 3 , R 4 and R 5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a pr…
- Who is the assignee on this patent?
- Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification A61K31/381. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).